Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 10/20 | 0.72 |
| ▸ | HTR1B | P28222 | 10/20 | 0.72 |
| ▸ | HTR1A | P08908 | 3/20 | 0.72 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6606931 | 1.00 | HTR1D (0.72) | HTR1DHTR1BHTR1APTPN11MAPT | |
| SCHEMBL6604399 | 0.88 | HTR1B (0.82) | HTR1DHTR1BHTR1APTPN11MAPT | |
| SCHEMBL6604404 | 0.88 | HTR1B (0.82) | HTR1DHTR1BHTR1APTPN11MAPT | |
| SCHEMBL6604602 | 0.85 | HTR1B (0.78) | HTR1DHTR1BHTR1APTPN11MAPT | |
| SCHEMBL6604606 | 0.85 | HTR1B (0.78) | HTR1DHTR1BHTR1APTPN11MAPT | |
| SCHEMBL6606999 | 0.84 | HTR1B (0.77) | HTR1DHTR1BHTR1APTPN11MAPT | |
| SCHEMBL6607001 | 0.84 | HTR1B (0.77) | HTR1DHTR1BHTR1APTPN11MAPT | |
| SCHEMBL6605819 | 0.84 | HTR1B (1.00) | HTR1DHTR1BHTR1AHTR2B | |
| SCHEMBL6605824 | 0.84 | HTR1B (1.00) | HTR1DHTR1BHTR1AHTR2B | |
| SCHEMBL6605202 | 0.82 | HTR1B (0.61) | HTR1DHTR1BHTR1APTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1190432-C | Piperazing derivatives as 5-HT1B antagonists | SMITHKLINE BEECHAM PLC (GB) | 2005-02-23 | — | — | CN | claimed |
| EP-1216239-B1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-11 | — | — | EP | claimed |
| CN-1190432-C | Piperazing derivatives as 5-HT1B antagonists | SMITHKLINE BEECHAM PLC (GB) | 2005-02-23 | — | — | CN | disclosed |
| US-20040176388-A1 | Piperazine derivatives as 5-HT1B antagonists | SMITHKLINE BEECHAM P.I.C. | 2004-09-09 | — | — | US | disclosed |
| US-6747030-B1 | CIS-6-(3,5-DIMETHYLPIPERAZIN-1-YL)-5-METHOXY-1-(2'-METHYL-4'-( 5-METHYL-1,2,4-OXADIAZOL-3-YL)BIPHENYL-4-CARBONYL)INDOLINE, ITS HYDROCHLORIDE SALT, OR ANOTHER PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; ANTIDEPRESSANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-06-08 | — | — | US | disclosed |
| EP-1216239-B1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-11 | — | — | EP | disclosed |
| CN-1399635-A | Piperazing derivatives as 5-HT1B antagonists | SMITHKLINE BEECHAM PLC (GB) | 2003-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176388-A1 | Piperazine derivatives as 5-HT1B antagonists | HTR1B, HTR2B, HTR2A | HTR1D 8/4885HTR1B 1/4885HTR1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.